Antitumor agent including low-dose irinotecan hydrochloride hydrate

• 收藏
• 分享

专利权人:

发明人:

Hiroyuki Okabe

申请号：

US14779759

公开号：

US09616081B2

申请日:

2014.03.27

申请国别(地区):

US

年份:

2017

代理人:

摘要：

Provided is a novel combination therapy using an FTD/TPI combination drug which exhibits remarkable antitumor effects, and few side effects.An antitumor agent is characterized in that the FTD/TPI combination drug is administered, using a reduced amount of trifluridine, at a dose in the range of 35 to 70 mg/m2/day and CPT-11 is administered at a dose in the range of 45 to 144 mg/m2/day.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/